The updated 2016 WHO classification of Central Nervous System tumors introduced a
novel concept of neuropathology diagnostics. Molecular parameters are now included
into the definition of several entities. This evolution from a previously purely histology-based
classification to an integrated approach of histology and genetic characteristics
has implications in daily diagnostic and clinical practice. Both the spectrum of diagnostic
workup demanded from the neuropathologist and the range of relevant markers to be
considered by clinicians and clinical investigators have increased. This article reviews
the major changes in the classification of diffuse gliomas, ependymoma, and medulloblastoma,
the practical consequences for diagnostics and clinical trials, and points toward
recent developments that potentially will influence the next update of the classification.
Keywords
2016 WHO classification - CNS tumors - glioma - astrocytoma - oligodendroglioma -
glioblastoma - molecular diagnosis - IDH - prognosis - diagnosis - medulloblastoma
- ependymoma
